Fermenta Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fermenta Biotech Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹70 became extra profit. Higher than 97% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹190 of operating cash. Higher than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹190Over the last 3 years, every ₹100 of reported profit came with ₹190 of operating cash.
Higher than 85% of Healthcare companies in India.
Self-Funding Ratio
3.3×Over the last 3 years its own operating cash covered its investment spending (capex) 3.3 times.
Higher than 82% of Healthcare companies in India.
Cash Locked Ratio
₹39For every ₹100 of sales, ₹39 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹35 tied up three years earlier.
More money tied up than 75% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹70Sales grew 50% in 3 years; of every extra ₹100 of sales, ₹70 became extra profit.
Higher than 97% of Healthcare companies in India.
Asset Productivity Ratio
+50% / +2%In 3 years sales changed by +50% while total assets changed by +2%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.9×Debt due within a year is covered 0.9 times by its yearly operating cash.
Lower than 54% of Healthcare companies in India.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 52% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 59% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 60% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Fermenta Biotech Limited owes ₹0.38 for every ₹1 it owns. Net profit fell 7% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
21.7Investors pay ₹21.7 for every ₹1 of Fermenta Biotech Limited's yearly profit, lower than 79% of Healthcare companies in India.
P/B ratio
3.18The share price is 3.18 times Fermenta Biotech Limited's book value per share, lower than 67% of Healthcare companies in India.
Market cap
₹1,292 CrThe total market value of all of Fermenta Biotech Limited's shares at today's price (share price × number of shares), smaller than 75% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹406 CrWhat Fermenta Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹141.68Net worth divided by the number of shares. The share price of ₹450.60 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
14.6%Fermenta Biotech Limited earned 14.6% on its shareholders' money over the last year, higher than 59% of Healthcare companies in India.
Owes vs Owns
0.38×Fermenta Biotech Limited owes ₹0.38 for every ₹1 it owns (low), higher than 53% of Healthcare companies in India.
Dividend yield
0.72%Fermenta Biotech Limited pays 0.72% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in India.
Revenue growth
+12%Revenue rose 12% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit growth
-7%Net profit fell 7% in the year to Mar 2026.
Profit margin
13.7%Fermenta Biotech Limited keeps ₹14 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Fermenta Biotech Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
8.1×Fermenta Biotech Limited's operating profit covered its interest costs 8.1 times in the year to Mar 2026.
Cash vs debt
Net debtFermenta Biotech Limited had ₹30 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Fermenta Biotech Limited's P/E ratio?
Investors pay ₹21.7 for every ₹1 of Fermenta Biotech Limited's yearly profit, lower than 79% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fermenta Biotech Limited: ₹1,292 Cr ÷ ₹406 Cr (31 Mar 2026) = 3.2.
What is Fermenta Biotech Limited's return on equity?
Fermenta Biotech Limited earned 14.6% on its shareholders' money over the last year, higher than 59% of Healthcare companies in India.
How much does Fermenta Biotech Limited owe compared with what it owns?
Fermenta Biotech Limited owes ₹0.38 for every ₹1 it owns (low), higher than 53% of Healthcare companies in India.
Does Fermenta Biotech Limited pay a dividend?
Yes. Fermenta Biotech Limited pays 0.72% of its share price as dividends a year, higher than 75% of dividend-paying Healthcare companies in India.
Is Fermenta Biotech Limited's revenue growing?
Revenue rose 12% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.